early-stage lung cancer
Conditions
Interventions
PMCT group:PMCT
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) The patient is over 18 years old. (2) Biopsy histology or cytology showed that the patient was pathologically confirmed to be lung cancer. The preoperative staging should meet the TNM staging in IASLC Version 8: T1a,N0,M0 or T1b,N0,M0, and the CTR should be less than or equal to 0.5. (3) There was no pathological high-risk ground glass nodule (single or multiple), the patient refused non-surgical biopsy or biopsy was not suitable, and the multi-disciplinary consultation (MDT) confirmed the use of ablation therapy; (4) Pulmonary function requirements: basic FEV1 > 40% predicted value, postoperative FEV1 > 30% predicted value, diffusion capacity > 40% predicted value, no hypoxemia or hypercapnia before surgery, exercise oxygen consumption > 50% predicted value. (5) The patient's quality of life score was consistent with Zubrod 0-2. (6) The patient is not suitable or unwilling to undergo surgery and external radiotherapy, and percutaneous ablation can be evaluated to achieve the purpose of radical treatment. (7) The patient signed informed consent and received microwave ablation surgery to treat the lung lesions.
Exclusion criteria
Exclusion criteria: Patients will not be admitted to the study if they meet any of the following criteria: 1. Severe bleeding tendency, platelet 18s, prothrombin activity < 40%). Anticoagulant therapy and/or antiplatelet agents have not been discontinued for more than 7 days prior to ablation; 1.5, hemoglobin < 110g/L; 2. Received radiotherapy or other surgical treatment within 6 months before the intended ablation; 3. Patients with diseases considered high risk for ablative surgery, such as severe comorbidification, infection period, immunocompromised function, renal insufficiency, severe pulmonary hypertension, severe heart disease, severe hypertension, and severe respiratory failure; 4. The nearest distance between the tumor and trachea, main bronchus, esophagus, aortic arch branch, main pulmonary artery, left and right pulmonary artery and heart is less than 2cm; 5. Have participated in or are participating in other clinical studies within the last 30 days; 6. Pregnant women, or patients with pregnancy plans during the study period; 7. Other conditions that the researcher determines need to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| five-year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year overall survival rate;disease-free survival,DFS;cancer-specific survival rates,CSS;Local recurrence free survival,LRFS;Pulmonary Function;QoL;Safety; | — |
Countries
China
Contacts
Public ContactZhang Xiaoju
Henan Provincial People's Hospital
Outcome results
None listed